SPD503 (Guanfacine Hydrochloride) in ADHD Plus Oppositional Symptoms

• Status: Completed
• Trial end date: 2008-01-04
• Target enrollment: 0
• Participant gender: All

Summary

To assess efficacy and safety of SPD503(guanfacine hydrochloride) in subjects with ADHD and oppositional symptoms.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Shire
• Treatments: Guanfacine

Criteria

Inclusion Criteria:

• Healthy subjects with ADHD and oppositional symptoms

• ADHD-RS>=24

• CGI >=4

• T-score of Opp subscale CPRS-R:L >=65

• Normal ECG and BP

• >= 55 lbs